Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects

Br J Pharmacol. 2010 Mar;159(6):1201-10. doi: 10.1111/j.1476-5381.2009.00613.x. Epub 2010 Feb 5.

Abstract

Background and purpose: Much interest is currently being focused on the anti-nociceptive effects mediated by nicotinic acetylcholine (nACh) receptors, including their location and mechanism of action. The purpose of this study was to elucidate these issues using 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine (5IA), a nACh receptor agonist, and [(125)I]5IA.

Experimental approach: We partially ligated the sciatic nerve of Sprague-Dawley rat to induce neuropathic pain [Seltzer's partial sciatic nerve ligation (PSL) model]. We then examined the changes in nACh receptor density in the CNS using [(125)I]5IA autoradiography and the involvement of nACh receptors in anti-nociceptive effects in the region where changes occurred.

Key results: Autoradiographic studies showed that the accumulation of [(125)I]5IA and the number of nACh receptors in the thalamus of PSL rats were increased about twofold compared with those in the sham-operated rats. No change was observed in other brain regions. Rats injected in the ventral posterolateral thalamic nucleus (VPL) with 5IA demonstrated a significant and dose-dependent anti-allodynic effect and this effect was completely antagonized by mecamylamine, injected with 5IA, into the VPL. The blockade of nACh receptors in the VPL by mecamylamine decreased by 70% the anti-allodynic effect of 5IA, given i.c.v. Moreover, mecamylamine given intra-VPL by itself, induced significant hyperalgesia.

Conclusions and implications: Our findings suggest that the nACh receptors expressed in the VPL play an important role in the anti-allodynic effects produced by exogenous and endogenous agonists.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoradiography
  • Azetidines / pharmacokinetics
  • Azetidines / pharmacology
  • Azetidines / therapeutic use*
  • Disease Models, Animal
  • Iodine Radioisotopes
  • Male
  • Nicotinic Agonists / pharmacokinetics
  • Nicotinic Agonists / pharmacology
  • Nicotinic Agonists / therapeutic use*
  • Pain / drug therapy*
  • Pain / metabolism
  • Pain Threshold
  • Pyridines / pharmacokinetics
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Nicotinic / biosynthesis*
  • Receptors, Nicotinic / physiology
  • Sciatic Neuropathy / drug therapy*
  • Sciatic Neuropathy / metabolism
  • Ventral Thalamic Nuclei / drug effects*
  • Ventral Thalamic Nuclei / metabolism

Substances

  • 5-iodo-3-(2-azetidinylmethoxy)pyridine
  • Azetidines
  • Iodine Radioisotopes
  • Nicotinic Agonists
  • Pyridines
  • Receptors, Nicotinic